A patent review of selective CDK9 inhibitors in treating cancer
暂无分享,去创建一个
R. Chen | Zhiyu Li | Jinlei Bian | Yi-ting Xu | Tizhi Wu | Jubo Wang | Xiaowei Wu | Yifan Xu
[1] Jung-Ae Kim,et al. CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells , 2023, Genes & Genomics.
[2] Zhanxiang Wang,et al. The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest , 2023, Cell Death & Disease.
[3] Oula El Atat,et al. Molecular targeted therapy: A new avenue in glioblastoma treatment. , 2022, Oncology letters.
[4] G. Curigliano,et al. ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’ , 2022, Expert opinion on investigational drugs.
[5] Xiu-ming Lu,et al. C-MYC Inhibited Ferroptosis and Promoted Immune Evasion in Ovarian Cancer Cells through NCOA4 Mediated Ferritin Autophagy , 2022, Cells.
[6] S. Peña-Llopis,et al. The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer , 2022, Cellular and Molecular Life Sciences.
[7] M. Loda,et al. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7. , 2022, Journal of cancer research and clinical oncology.
[8] S. Knapp,et al. Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. , 2022, Journal of medicinal chemistry.
[9] J. Byrd,et al. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia , 2022, Leukemia.
[10] Tian Xie,et al. Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy. , 2022, European journal of medicinal chemistry.
[11] S. Hehlgans,et al. Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy , 2022, Cancers.
[12] W. Liu,et al. SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9 , 2022, Frontiers in Pharmacology.
[13] S. Gou,et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. , 2022, European journal of medicinal chemistry.
[14] W. Pao,et al. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. , 2022, Journal of medicinal chemistry.
[15] Kaixian Chen,et al. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer. , 2022, Journal of medicinal chemistry.
[16] D. Taatjes,et al. Chemical inhibitors of transcription-associated kinases. , 2022, Current opinion in chemical biology.
[17] Yan Fan,et al. CDK9 inhibitors in cancer research. , 2022, RSC Medicinal Chemistry.
[18] Yadong Chen,et al. Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies. , 2022, European journal of medicinal chemistry.
[19] A. Alimonti,et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer , 2022, Nature Communications.
[20] Yuetong Wang,et al. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis , 2022, Cell death & disease.
[21] P. Antosik,et al. The Prognostic Role of CDK9 in Bladder Cancer , 2022, Cancers.
[22] K. Bhalla,et al. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells , 2022, Blood cancer journal.
[23] K. Garber. The PROTAC gold rush , 2021, Nature biotechnology.
[24] Fangbing Liu,et al. Cotargeting of Bcl-2 and Mcl-1 Shows Promising Antileukemic Activity against AML Cells Including those with Acquired Cytarabine Resistance. , 2021, Experimental Hematology.
[25] A. Ferguson,et al. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. , 2021, Journal of medicinal chemistry.
[26] Qiulian Wu,et al. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. , 2021, Cancer discovery.
[27] S. Bharate,et al. Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline , 2021, Medicinal research reviews.
[28] C. Leung,et al. Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer , 2021, Acta pharmaceutica Sinica. B.
[29] Yu-bo Zhou,et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. , 2021, Journal of medicinal chemistry.
[30] Hong Liu,et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. , 2021, Journal of medicinal chemistry.
[31] G. Gomatou,et al. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials , 2021, Clinical and Translational Oncology.
[32] Q. Mo,et al. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells , 2021, Cancers.
[33] H. Briem,et al. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. , 2021, Journal of medicinal chemistry.
[34] C. Leung,et al. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells , 2021, Genes & diseases.
[35] M. Gilbert,et al. Targeting CDK9 for the Treatment of Glioblastoma , 2021, Cancers.
[36] Tariq Ahmad Masoodi,et al. Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer , 2021, Journal of Ovarian Research.
[37] Shudong Wang,et al. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents , 2021, Frontiers in Oncology.
[38] K. Strebhardt,et al. Targeting CDK9 for Anti-Cancer Therapeutics , 2021, Cancers.
[39] S. Guhan,et al. The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma. , 2021, Journal of Investigative Dermatology.
[40] Tuersunayi Abudureheman,et al. CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism , 2021, Frontiers in Cell and Developmental Biology.
[41] Fen Ma,et al. Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer , 2021, Molecular oncology.
[42] F. Appelbaum,et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[43] Aisha A. Alsfouk. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy , 2021, Journal of enzyme inhibition and medicinal chemistry.
[44] Jianbing Hou,et al. CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9 , 2021, Cell death & disease.
[45] A. Ferguson,et al. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. , 2020, Journal of medicinal chemistry.
[46] R. Montironi,et al. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications , 2020, Cells.
[47] Y. Zhuang,et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway , 2020, British Journal of Cancer.
[48] N. Lu,et al. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling. , 2020, Cancer letters.
[49] Charles Y. Lin,et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. , 2020, Cell chemical biology.
[50] Zhiyu Li,et al. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. , 2020, Journal of medicinal chemistry.
[51] Yanmin Zhang,et al. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. , 2020, European journal of medicinal chemistry.
[52] Xiuling Zhi,et al. CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. , 2020, American journal of cancer research.
[53] S. Fawell,et al. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells , 2019, Clinical Cancer Research.
[54] L. Selth,et al. Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro , 2019, Oncology Abstracts.
[55] H. Ding,et al. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity. , 2019, European journal of medicinal chemistry.
[56] L. Drew,et al. Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models , 2019, Molecular and Cellular Biology / Genetics.
[57] X. Tian,et al. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. , 2019, European journal of medicinal chemistry.
[58] Z. Duan,et al. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma , 2018, EBioMedicine.
[59] Lindsey A. Marsh,et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer , 2018, Oncotarget.
[60] J. Espinosa,et al. Therapeutic targeting of transcriptional cyclin-dependent kinases , 2018, Transcription.
[61] C. Zahnow,et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer , 2018, Cell.
[62] I. D’Orso,et al. CDK9: a signaling hub for transcriptional control , 2018, Transcription.
[63] L. Drew,et al. Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1 , 2018, Molecular and Cellular Biology / Genetics.
[64] H. Briem,et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer , 2017, ChemMedChem.
[65] R. Young,et al. Transcriptional Addiction in Cancer , 2017, Cell.
[66] Sonali M. Smith,et al. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial , 2017, Leukemia & lymphoma.
[67] Y. Fernández-Marrero,et al. Survival control of malignant lymphocytes by anti-apoptotic MCL-1 , 2016, Leukemia.
[68] Daniel C. Factor,et al. RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. , 2016, The Journal of clinical investigation.
[69] Mu-Kuan Chen,et al. Transcriptional regulation of Mcl-1 plays an important role of cellular protective effector of vincristine-triggered autophagy in oral cancer cells , 2015, Expert opinion on therapeutic targets.
[70] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[71] John G. Moffat,et al. Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.
[72] J. Butera. Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial. , 2013, Journal of medicinal chemistry.
[73] J. Karn,et al. Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes , 2013, PLoS pathogens.
[74] W. Hahn,et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. , 2010, Molecular endocrinology.
[75] Jitender Verma,et al. 3D-QSAR in drug design--a review. , 2010, Current topics in medicinal chemistry.
[76] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[77] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[78] Q. Zheng,et al. CDK inhibitors in cancer therapy, an overview of recent development. , 2021, American journal of cancer research.
[79] R. Roskoski. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. , 2019, Pharmacological research.